Rh0(D) Immunoglobulin (RhIG)

How to Cite This Chapter: Morin P-A, Ning S, Łętowska M, Rosiek A. Rh0(D) Immunoglobulin (RhIG). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.II. Accessed July 23, 2024.
Last Updated: October 19, 2023
Last Reviewed: October 19, 2023
Chapter Information

Rh0(D) immunoglobulin (RhIG) is a blood product that contains anti-D immunoglobulins derived from human blood donors administered for the purpose of preventing RhD alloimmunization.


RhIG is most commonly administered to nonalloimmunized, RhD-negative women during pregnancy, following delivery, and at the time of any complications of pregnancy during which fetal-maternal blood exchange may occur. The dosage administered depends on a variety of factors, including timing in and after pregnancy, extent of fetal-maternal blood exchange, manufacturer recommendations, and jurisdictional guidelines.

Indications for RhIG administration outside of pregnancy include administration of RhD-positive platelets to an RhD-negative recipient, prevention of RhD alloimmunization, and treatment of immune thrombocytopenia (ITP).

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.